TSTakashi Sozu

Takashi Sozu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takashi Sozu has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Community periodontal index based screening findings and healthcare expenditures: a 7-year cohort study of male employees in Japan

    by Keiichi Matsuzaki, Takashi Sozu, Takashi Kawamura

    Background: The global economic burden of dental diseases, particularly periodontitis, is substantial, with growing evidence linking these conditions to systemic diseases such as diabetes and cardiovascular diseases. Although international studies have demonstrated that periodontal treatment can mitigate medical costs, comprehensive research examining the relationship among oral health, healthcare expenditures, and systemic disease onset is still scarce, particularly in Japan. Therefore, this study examined the associations among oral health, medical and dental expenditures, and the incidence of lifestyle-related diseases, using annual health checkup data. Methods: This 7-year cohort study analyzed data from 467 male employees who participated in annual health and dental check-ups from 2007 to 2014. Participants were categorized into CPI ≥ 3 group (at least one tooth) and CPI < 3 group based on the community periodontal index. We compared baseline characteristics and healthcare expenditures (medical, dental, pharmaceutical and total healthcare) between two groups. Longitudinal changes in glycated hemoglobin (HbA1c) levels were evaluated using a mixed model for repeated measures. Results: Participants in the CPI ≥ 3 group ( n = 87) were significantly older than the CPI < 3 group ( n = 380). Regarding median annual expenditures, dental expenditure (¥12,760 vs. ¥7,030; p = 0.01), and total healthcare expenditure (¥97,030 vs. ¥51,415; p = 0.03) were significantly higher in the CPI ≥ 3 group in unadjusted GLM analyses, whereas medical expenditure (¥41,160 vs. ¥21,770; p = 0.11) was not. In age adjusted analyses, only dental expenditure remained independently and significantly higher (mean difference: ¥12,692; p = 0.03). No significant difference in HbA1c trajectories or the risk of exceeding an HbA1c threshold of 5.6% or 6.5% was observed between the two groups. Conclusion: Our findings suggest that a CPI-based screening finding of ≥ 3 is independently associated with higher long-term dental expenditures. Promoting corporate CPI-based screening as a low-threshold, population-level marker has the potential to serve as a strategy for identifying individuals at risk for elevated healthcare burdens.

  • Open Access

    Dose Optimization Design for Randomized Phase II Trials With Toxicity and Efficacy Endpoints

    by Ryuta Tabata, Tomohiro Ohigashi, Takashi Sozu

    Several study designs for identifying optimal biological dose (OBD) have been proposed for phase I, II, and I/II clinical trials, considering toxicity and efficacy of anticancer drugs, especially molecular‐targeted therapies and immune checkpoint inhibitors. Among these, the multiple‐dose randomized phase II trial (MERIT) design selects OBD candidates using hypothesis testing for toxicity and efficacy outcomes. However, it does not consistently control the type I error rate below the significance level, as the null hypothesis is defined only at specific points in a two‐dimensional null space. To address this limitation, we developed a design treating toxicity and efficacy as co‐primary endpoints, ensuring strict dose‐level type I error control across the entire null space. A Bonferroni correction addressed multiplicity in dose selection, providing overall type I error control. Unlike the existing method, the rejection region is determined analytically rather than by simulation, reducing computational costs. The type I error rate of the existing method exceeds the significance level in regions outside points considered in its sample size calculation. By contrast, the proposed method maintains the type I error rate below the significance level across the null space, though conservatively due to the co‐primary endpoint framework and Bonferroni adjustment. Required sample sizes of the proposed method tend to be larger than those of the existing one.

  • Open Access

    Experienced stigma in Japanese outpatients with diabetes: Age and polypharmacy matter

    by Haremaru Kubo, Takashi Sozu, Reina Beng Mitsunaga, Hiromasa Hazama, Naohiro Sekikawa, Ryota Wada, Yuko Watanabe, Akira Tamura, Toshiro Yamazaki, Setsu Ohta, et al.

    There are three types of diabetes-related stigma (DRS): perceived, experienced, and internalized, all of which negatively impact individuals with diabetes. Over the past 2 decades, research in Japan has grown, highlighting the significant clinical effects of DRS. In this study, we focused on the least-studied form, experienced stigma investigating its prevalence, clinical correlates, and the awareness of DRS and advocacy activities among Japanese people with diabetes. We conducted a single-center, cross-sectional study from April 3 to 28, 2023, at the Ohta Nishinouchi Hospital Diabetes Center in Japan, involving 114 adults with type 1 or type 2 diabetes. Participants with severe mental or physical conditions were excluded. Each participant completed a questionnaire assessing experienced stigma, the impact of diabetes on their social life, and their familiarity with the terms “diabetes stigma” and “advocacy activities.” Associations between reported stigma and demographic or clinical factors were analyzed statistically. Our findings showed that only 19.3% of participants reported a significant impact of DRS on their social life, with younger individuals and those on multiple diabetes medications more likely to report experiencing stigma. Additionally, awareness of “diabetes stigma” and “advocacy activities” was notably low among participants. In conclusion, compared to international studies, the prevalence of experienced stigma among Japanese individuals with diabetes appears lower, based on this single-center face-to-face study of outpatients. However, age and polypharmacy were identified as significant factors associated with increased reports of stigma. Despite the limitations of a single-center design, small sample size, and use of non-validated survey tools, the observed low awareness of “diabetes stigma” and “advocacy activities” underscored the need for enhanced educational initiatives by healthcare professionals and diabetes-related organizations in Japan.

  • Dynamic Prediction of Analysis Timing in Clinical Trials Using Joint Models of Longitudinal and Time‐to‐Event Data

    by Ryunosuke Machida, Kentaro Sakamaki, Tomohiro Ohigashi, Takashi Sozu

    In confirmatory clinical trials with a time‐to‐event endpoint, the timing of the analysis is often determined based on the observed number of events. In such event‐driven trials, the analysis timing is inherently uncertain, making its accurate prediction crucial for optimizing trial costs, personnel allocation, and resource management. Although various methods for predicting analysis timing have been extensively studied under different assumptions, these approaches predominantly rely on data pertaining to the primary endpoint when estimating the time‐to‐event distribution. To the best of our knowledge, no existing method incorporates longitudinally measured data, such as prostate‐specific antigen (PSA) levels in prostate cancer trials. We developed a method for predicting analysis timing within the framework of dynamic prediction using joint models that account for longitudinally measured covariates and time‐to‐event outcomes. Furthermore, we assessed the prediction performance by comparing it against two alternative methods based on the degree of covariate data: (1) a method without covariates, (2) a method using only baseline covariates, and (3) the proposed method using baseline and longitudinally measured covariates. Numerical experiments demonstrated that the proposed method enhances the accuracy of analysis timing predictions compared with methods that do not utilize longitudinally measured covariates. The proposed method is valuable for accurately predicting analysis timing when longitudinally measured covariates are available.


  • Comparison of parametric and hybrid methods for estimating mean survival time in clinical study

    by Yuki Nakagawa, Takashi Sozu

    The mean survival time (MST) is usually estimated as the area under the curve of the estimated survival function obtained using the Kaplan-Meier method. However, when the maximum observed survival time is censored, the MST cannot be estimated because the survival function does not reach zero. In such cases, parametric and hybrid methods are used to estimate the MST. The parametric method assumes a probability distribution throughout the entire time and has been evaluated in several studies. The hybrid method combines two approaches: it first applies the Kaplan-Meier method up to a specified time point and then extrapolates the survival curve beyond this point using a parametric distribution. Evaluation of the performance of the hybrid method is limited to a few data-generating mechanisms and analysis models. This study evaluated the performance of the parametric and hybrid methods through numerical experiments, assuming nine probability distributions for the data-generating mechanism and 16 analysis models. The bias and root mean square error of the generalized gamma model and the Royston-Parmar models with the log(-log) link function tended to be smaller than those of the other analysis models, even when the assumed probability distribution of the analysis model was inconsistent with that of the data-generating mechanism when the sample size is relatively large. Overall, the performances of the parametric and hybrid methods were comparable across all the data-generating mechanisms.

  • Open Access

    Nonparametric Bayesian approach for dynamic borrowing of historical control data

    by Tomohiro Ohigashi, Kazushi Maruo, Takashi Sozu, Masahiko Gosho

    When incorporating historical control data into the analysis of current randomized controlled trial data, it is critical to account for differences between the datasets. When the cause of difference is an unmeasured factor and adjustment for only observed covariates is insufficient, it is desirable to use a dynamic borrowing method that reduces the impact of heterogeneous historical controls. We propose a nonparametric Bayesian approach that addresses between-trial heterogeneity and allows borrowing historical controls homogeneous with the current control. Additionally, to emphasize conflict resolution between historical controls and the current control, we introduce a method based on the dependent Dirichlet process (DP) mixture. The proposed methods can be implemented using the same procedure, regardless of whether the outcome data comprise aggregated study-level data or individual participant data. We also develop a novel index of similarity between the historical and current control data, based on the posterior distribution of the parameter of interest. We conduct a simulation study and analyze clinical trial examples to evaluate the performance of the proposed methods compared to existing methods. The proposed method, based on the dependent DP mixture, can accurately borrow from homogeneous historical controls while reducing the impact of heterogeneous historical controls compared to the typical DP mixture. The proposed methods outperform existing methods in scenarios with heterogeneous historical controls, in which the meta-analytic approach is ineffective.


  • Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial)

    by Shin Ito, Yuri Nakajima, Hiroki Fukuda, Chisato Izumi, Gaku Nakazawa, Hajime Yamashita, Hideo Matsuhisa, Moriaki Inoko, Shigeru Toyoda, Shin Takiuchi, et al.

    Background Recent large clinical trials have revealed that sodium–glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes not only in patients with heart failure with reduced ejection fraction, but also in patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF). However, the effect of SGLT2 inhibitors on left ventricular (LV) diastolic function is still controversial. Methods and Results The TOP-HFPEF trial (Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus) is a multicenter, double-arm, open-label, confirmatory, investigator-initiated clinical study to investigate the effect of SGLT2 inhibitor on LV diastolic function in patients with HFpEF and type 2 diabetes mellitus. The participants are randomly assigned (1:1) to the tofogliflozin group (20 mg once daily) or the control group (administration or continuation of antidiabetic drugs other than SGLT2 inhibitors). The estimated number of patients to be enrolled in this trial is 90 in total (45 in each group). The participants are followed up for 52 weeks with tofogliflozin or control drugs. The primary endpoint is the change in E/e′ assessed by echocardiography from the baseline to the end of this study (52 weeks). This trial will also evaluate the effects of tofogliflozin on cardiovascular events, biomarkers, other echocardiographic parameters, the occurrence of atrial fibrillation, and renal function. Conclusions The TOP-HFPEF trial will clarify the efficacy of an SGLT2 inhibitor, tofogliflozin, on LV diastolic function in patients with HFpEF and type 2 diabetes mellitus.


  • Open Access

    Identification of High-Risk Groups in Urinalysis: Lessons from the Longitudinal Analysis of Annual Check-Ups

    by Keiichi Matsuzaki, Tomohiro Ohigashi, Takashi Sozu, Mami Ishida, Daisuke Kobayashi, Hitoshi Suzuki, Yusuke Suzuki, Takashi Kawamura

    Background: For effective screening in urinalysis, information on high-risk groups is needed; however, there is a lack of evidence in young adults in particular. The aim of this study was to provide information on urinalysis in young adults and to identify high-risk groups of urinalyses using multi-year data obtained from annual large-scale check-ups. Method: We used annual health check-up data collected from 2011 to 2016 at Kyoto University in Japan. Eligible participants were those aged 18–39 years who underwent annual health check-ups for four consecutive years between 2011 and 2016. We conducted descriptive analyses and calculated the risk ratios (RRs) for urinary abnormalities in the fourth year of urinalysis. Results: In total, 13,640 participants (10,877 men, 79.7%) met the eligibility criteria. The mean prevalence rates of proteinuria, haematuria and glucosuria were 1.61% (men: 1.63%; women: 1.53%), 1.48% (men: 0.53%; women: 5.22%) and 0.46% (men: 0.52%; women: 0.25%), respectively. Participants with urinary abnormalities at least once in the initial 3 years had a higher risk of urinary abnormalities in the fourth year than participants with no abnormal findings in the initial 3 years; the risk ratios (RRs) of proteinuria, haematuria and glucosuria were 3.5 (95% confidence interval (CI) = 3.2–3.7), 12.2 (95% CI = 11.7–12.7) and 42.6 (95% CI = 37.7–48.1), respectively. The RRs of all urinary abnormalities in the fourth year increased as the frequency of urinary abnormalities over the preceding 3 years increased. In haematuria, differences of the RR were observed between men and women. Conclusion: We clarified the prevalence of urinary abnormalities in young adults and high-risk groups of urinary abnormalities. Our findings support the need for multi-year annual urinalysis.


  • Open Access

    Flexible use of copula‐type model for dose‐finding in drug combination clinical trials

    by Koichi Hashizume, Jun Tshuchida, Takashi Sozu

    Identification of the maximum tolerated dose combination (MTDC) of cancer drugs is an important objective in phase I oncology trials. Numerous dose‐finding designs for drug combination have been proposed over the years. Copula‐type models exhibit distinctive advantages in this task over other models used in existing competitive designs. For example, their application enables the consideration of dose‐limiting toxicities attributable to one of two agents. However, if a particular combination therapy demonstrates extremely synergistic toxicity, copula‐type models are liable to induce biases in toxicity probability estimators due to the associated Fréchet–Hoeffding bounds. Consequently, the dose‐finding performance may be worse than those of other competitive designs. The objective of this study is to improve the performance of dose‐finding designs based on copula‐type models while maintaining their advantageous properties. We propose an extension of the parameter space of the interaction term in copula‐type models. This releases the Fréchet–Hoeffding bounds, making the estimation of toxicity probabilities more flexible. Numerical examples in various scenarios demonstrate that the performance (e.g., the percentage of correct MTDC selection) of the proposed method is better than those exhibited by existing copula‐type models and comparable with those of other competitive designs, irrespective of the existence of extreme synergistic toxicity. The results obtained in this study could motivate the real‐world application of the proposed method in cases requiring the utilization of the properties of copula‐type models.


  • Open Access

    Matrix decomposition in meta‐analysis for extraction of adverse event pattern and patient‐level safety profile

    by Kentaro Matsuura, Jun Tsuchida, Shuji Ando, Takashi Sozu

    The purpose of assessing adverse events (AEs) in clinical studies is to evaluate what AE patterns are likely to occur during treatment. In contrast, it is difficult to specify which of these patterns occurs in each patient. To tackle this challenging issue, we constructed a new statistical model including nonnegative matrix factorization by incorporating background knowledge of AE‐specific structures such as severity and drug mechanism of action. The model uses a meta‐analysis framework for integrating data from multiple clinical studies because insufficient information is derived from a single trial. We demonstrated the proposed method by applying it to real data consisting of three Phase III studies, two mechanisms of action, five anticancer treatments, 3317 patients, 848 AE types, and 99,546 AEs. The extracted typical treatment‐specific AE patterns coincided with medical knowledge. We also demonstrated patient‐level safety profiles using the data of AEs that were observed by the end of the second cycle.